Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
Houeto
J L
JL
Mesnage
V
V
Welter
M L
ML
Mallet
L
L
Agid
Y
Y
Bejjani
B P
BP
D003221:Confusion / Q000209:etiology; D003863:Depression / Q000139:chemically induced; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D005500:Follow-Up Studies; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D019964:Mood Disorders / Q000209:etiology; D009459:Neuroleptic Malignant Syndrome / Q000517:prevention & control; D010300:Parkinson Disease / Q000628:therapy*; D011788:Quality of Life; D012920:Social Behavior Disorders / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D020531:Subthalamic Nucleus / Q000502:physiology; D013995:Time; D016896:Treatment Outcome
D018491:Dopamine Agonists; D007980:Levodopa